ALKS Stock: Price, Earnings History and SEC Filings
Alkermes plc (ALKS) last traded at $45.34, down 0.07% on the latest session and up 11.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.00 against an analyst estimate of $-0.04, a beat of 100.0%.
$45.34 -0.07%
1 month+11.90%
52-week high$55.67
52-week low$27.00
Volume1.11M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ALKS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 28, 2026 | $0.00 | $-0.04 | +100.00% |
| Mar 2026 | May 5, 2026 | $-0.40 | $-0.57 | +29.82% |
| Dec 2025 | Feb 25, 2026 | $0.34 | $0.31 | +9.68% |
| Sep 2025 | Oct 28, 2025 | $0.49 | $0.34 | +44.12% |
ALKS beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for ALKS
SEC filing data is not available right now. You can search for ALKS on SEC EDGAR.
ALKS news
- Alkermes (ALKS) Starts Phase 2 MDD Trial, Is The Upside Already Priced In?Oct 31, 2026 · finance.yahoo.com
- Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)Oct 30, 2026 · finance.yahoo.com
- Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top EstimatesOct 29, 2026 · finance.yahoo.com
- Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another StoryOct 29, 2026 · seekingalpha.com
- Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to DeclineOct 27, 2026 · finance.yahoo.com
- Alkermes to Report Third Quarter Financial Results on November 3, 2026Oct 20, 2026 · finance.yahoo.com
- Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to DeclineOct 20, 2026 · finance.yahoo.com
- Alkermes plc (ALKS) Stock Analysis: A Strong Buy with a 36% Upside PotentialOct 19, 2026 · directorstalkinterviews.com
About Alkermes plc
Alkermes plc (ALKS) is a US-listed public company on Nasdaq.